<DOC>
	<DOCNO>NCT02859623</DOCNO>
	<brief_summary>Blastic plasmacytoid dendritic cell neoplasm ( BPDCN ) rare disease characterize aggressive clinical behavior poor prognosis . It predominantly affect elderly male average age 67 year diagnosis affect organ usually skin , bone marrow , lymph node central nervous system . Patients BPDCN poor outcome median overall survival ( OS ) range large series patient 8 12 month . Patient care must define pathology . Despite 40 % -90 % complete remission ( CR ) rate initial chemotherapy , relapse almost inevitable . The investigator develop national network collect clinical biological data French patient diagnose BPDCN .</brief_summary>
	<brief_title>Descriptive Study Efficacy Treatments Blastic Dendritic Cell Neoplasm ( BPDCN )</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Patients diagnose blastic plasmacytoid dendritic cell neoplasm ( BPDCN ) January 2000 June 2013 France . Diagnosis establish hematology laboratory French blood Agency Bourgogne FrancheComt√© and/or anatomopathological analysis ( realize local centre Tony Petrella Dijon University Hospital ) accord phenotypic anatomopathological criterion publish literature . No exclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>